Heidelberg Pharma AG

XTRA:HPHA 주식 보고서

시가총액: €112.3m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Heidelberg Pharma 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Andreas Pahl

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기less than a year
CEO 소유권n/a
경영진 평균 재임 기간1.5yrs
이사회 평균 재임 기간12.3yrs

최근 관리 업데이트

Recent updates

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Feb 16
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Dec 05
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Jul 21
Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Oct 16
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Nov 28
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Mar 27
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Mar 15
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Jan 17
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Dec 14
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

CEO 보상 분석

Andreas Pahl 의 보수는 Heidelberg Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
May 31 2024n/an/a

-€13m

Feb 29 2024n/an/a

-€18m

Nov 30 2023n/an/a

-€20m

Aug 31 2023n/an/a

-€22m

May 31 2023n/an/a

-€27m

Feb 28 2023n/an/a

-€19m

Nov 30 2022€328k€240k

-€20m

Aug 31 2022n/an/a

-€21m

May 31 2022n/an/a

-€22m

Feb 28 2022n/an/a

-€27m

Nov 30 2021€442k€240k

-€26m

Aug 31 2021n/an/a

-€25m

May 31 2021n/an/a

-€22m

Feb 28 2021n/an/a

-€20m

Nov 30 2020€295k€207k

-€18m

Aug 31 2020n/an/a

-€17m

May 31 2020n/an/a

-€15m

Feb 29 2020n/an/a

-€12m

Nov 30 2019€288k€200k

-€10m

Aug 31 2019n/an/a

-€10m

May 31 2019n/an/a

-€11m

Feb 28 2019n/an/a

-€12m

Nov 30 2018€286k€200k

-€12m

Aug 31 2018n/an/a

-€11m

May 31 2018n/an/a

-€11m

Feb 28 2018n/an/a

-€11m

Nov 30 2017€241k€171k

-€11m

보상 대 시장: German 시장에서 비슷한 규모의 회사에 비해 Andreas 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Andreas 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Andreas Pahl

less than a year

테뉴어

€328,276

보상

Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...

리더십 팀

이름위치테뉴어보상소유권
Andreas Pahl
CEO & Spokesman of the Executive Boardless than a year€328.28k데이터 없음
Walter Miller
Chief Financial Officer1.3yrs데이터 없음데이터 없음
Jorg Kemkowski
Chief Operating Officer1.7yrs데이터 없음데이터 없음
Sylvia Wimmer
Director Corporate Communicationno data데이터 없음데이터 없음
Andras Strassz
Chief Medical Officer3.5yrs데이터 없음데이터 없음
George Badescu
Chief Business Officerno data데이터 없음데이터 없음

1.5yrs

평균 재임 기간

경험이 풍부한 관리: HPHA 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Friedrich von Bohlen und Halbach
Member of the Supervisory Board19.4yrs€24.77k데이터 없음
Georg Baur
Deputy Chairman of the Supervisory Board24.7yrs€40.25k데이터 없음
Christof Hettich
Chairman of Supervisory Board14.3yrs€52.50k데이터 없음
Birgit Kudlek
Member of the Supervisory Board12.3yrs€27.33k데이터 없음
Mathias Hothum
Deputy Chairman of Supervisory Board9.2yrs€35.50k데이터 없음
Dongzhou Liu
Member of Supervisory Board2.3yrs€5.08k데이터 없음
Yan Xia
Member of Supervisory Board1.3yrs데이터 없음데이터 없음

12.3yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: HPHA 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.1 년).